In this Institutional Review Board approved protocol of Cleveland Clinic, we retrospectively evaluated the effects of BTK inhibitors ibrutinib and acalabrutinib therapy in patients (n = 4) with IgM-related AL amyloidosis due to underlying WM. Here, CD40LG is linked to AL amyloidosis.